Aguiar Eric
SEC-identified person · CIK 1262325 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Bridgebio Pharma, Inc. BBIO | Director | filed 2019 - 2026 |
| Biomea Fusion, Inc. BMEA | Director | filed 2021 - 2026 |
| Invitae Corp NVTA | Director | filed 2015 - 2023 |
| Eidos Therapeutics, Inc. EIDX | Director | filed 2018 - 2020 |
| Biohaven Pharmaceutical Holding Co Ltd. BHVN | Director | filed 2017 - 2020 |
| Tranzyme INC TZYM | Officer | filed 2013 - 2013 |
| Activbiotics INC HAQ | Officer | filed 2007 - 2007 |
| Pharmathene, INC PIP | Officer | filed 2007 - 2007 |
| Middlebrook Pharmaceuticals, Inc. MBRKQ | Officer | filed 2007 - 2007 |
| Replidyne INC RDYN | Officer | filed 2006 - 2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.